Skip to content
Healing & Recovery Not approved for human use in Australia; studied in preclinical and research settings only. No marketed human therapeutic product.

TB-500

Also known as: Thymosin Beta-4 (fragment), TB4

TB-500 is a synthetic peptide related to the naturally occurring protein Thymosin Beta-4. It is discussed online for reported effects on tissue repair and flexibility, though human evidence is very limited.

Category
Healing & Recovery
Reported half-life
Not well established; limited data and varies by study
Common forms
Lyophilised powder for reconstitution, Injectable solution
Research status
Not approved for human use in Australia; studied in preclinical and research settings only. No marketed human therapeutic product.
Last updated
21 June 2026

Claimed effects

The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.

  • Reported to support muscle, tendon and ligament recovery (largely animal/preclinical data)
  • Claimed to promote cell migration and new blood-vessel formation
  • Users report improved flexibility and reduced injury-related discomfort
  • Early research indicates possible roles in wound healing and inflammation modulation

How it is reported to work

TB-500 is a fragment associated with Thymosin Beta-4, a protein reported to regulate actin, a building block of cells involved in movement and repair. It is reported to encourage cell migration to injured sites and to support angiogenesis (formation of new blood vessels). These mechanisms come mostly from laboratory and animal studies, and their relevance to humans is not established.

Background

TB-500 is a synthetic peptide commonly described as a fragment or analogue related to Thymosin Beta-4 (TB4), a naturally occurring protein involved in cellular repair processes. It frequently appears alongside BPC-157 in discussions about injury recovery. As with everything on this site, the information here is educational, not medical advice, and the effects described are claimed and reported rather than proven in humans.

What the research actually shows

Research on Thymosin Beta-4 and TB-500 is dominated by laboratory and animal studies. These suggest the molecule may play a role in cell migration, blood-vessel formation and tissue repair. Robust, peer-reviewed human clinical trials demonstrating safety and effectiveness are not available, so claimed benefits remain unverified.

AspectStatus
Preclinical/animal dataPresent, hypothesis-generating
Human clinical trialsVery limited
Australian approvalNone

What people use it for (reported)

Within online communities, people report using TB-500 in attempts to recover from soft-tissue injuries and to improve perceived flexibility and mobility. These are anecdotal accounts. Studies suggest mechanisms involving actin regulation and angiogenesis, but no reported effect should be treated as an established outcome.

Things to be aware of

TB-500 is not approved for human use in Australia. Grey-market products may vary widely in purity and content, which is part of why independent testing is discussed in this space, verifying what is actually in a vial is something users cannot do by sight alone. Because controlled human safety data does not exist, long-term risks are unknown.

If you are dealing with an injury, the responsible path is a conversation with a qualified healthcare professional, not self-experimentation. This page exists to help readers understand TB-500 and the evidence around it. It is not an endorsement, and it does not recommend obtaining or using the compound. Claimed effects are not established medical facts.

Reported positives & side effects

Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.

Reported positives

  • Reported to support recovery of muscle, tendon and ligament injuries
  • Users report improved flexibility and range of motion
  • Reported to reduce injury-related inflammation and discomfort
  • Anecdotally reported to aid recovery in chronic or stubborn soft-tissue issues
  • Reported less frequent dosing than some other recovery peptides due to longer-lasting effects

Common side effects

  • Injection-site reactions such as redness, swelling or bruising
  • Fatigue or lethargy reported in the hours after dosing
  • Head-rush or light-headedness reported by some users
  • Temporary flu-like feeling reported anecdotally

Rare / serious side effects

  • Heart palpitations reported anecdotally by some users
  • Allergic-type reactions
  • Reactions attributed to impurities in unregulated grey-market product
  • Unknown long-term effects due to absence of controlled human safety trials

Reported misuse & overdose risks

What has been reported to happen with overuse, excessive dosing, or long-term misuse of TB-500. Listed so you can make an informed decision, not to suggest any use is safe.

  • Because TB-500 is reported to promote cell migration and angiogenesis, there is a frequently raised theoretical concern that overuse could support growth of existing tumours, unproven but a key reason caution is advised
  • Extended continuous use beyond reported loading and maintenance phases is discouraged given entirely unknown long-term safety
  • Unverified grey-market vials are reported to risk contamination, incorrect dosing and infection from non-sterile reconstitution
  • Using TB-500 to push through an injury rather than rest it is reported to risk worsening the underlying damage
  • Stacking with multiple other peptides is reported to make side effects and benefits impossible to attribute

Reported results timeline

Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Effects are generally reported to build more gradually than some peptides, with noticeable changes reported over several weeks rather than days.

  1. First effects

    Subtle changes within the first week

  2. Noticeable change

    Improved mobility ~3-4 weeks

  3. Clear results

    Reported recovery progress by ~6-8 weeks

Commonly reported dosing & protocol

Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take TB-500. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.

Commonly reported dosing for TB-500
RouteSubcutaneous injection
Typical reported doseReported community figures of roughly 2–2.5 mg per dose
FrequencyReported as a loading phase of about 2× per week, then a weekly maintenance dose
Cycle lengthReported total cycles of about 4–8 weeks, then a break

Reported reconstitution (mg → units)

Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 2 mg dose ≈ 0.8 mL = 80 units on a U-100 insulin syringe; a full 2.5 mg dose ≈ 1.0 mL = 100 units.

Work out the units for your vial → Calculator

Commonly reported community patterns describe a loading phase over the first few weeks followed by a lower maintenance dose, with total cycles often reported around 4 to 8 weeks before a break. Less frequent injections (e.g. once or twice weekly) are reported due to its longer duration. These are reported patterns only, not a recommendation, and no human dose is medically validated.

Best used with / commonly stacked with

Combinations people report using together. Reported, not recommended, stacking can increase risks.

BPC-157

Very commonly reported together as a recovery pair, with users reporting complementary healing effects

Ipamorelin

Reported to be added for recovery, sleep and body-composition support

CJC-1295

Reported in growth-hormone-focused recovery stacks alongside healing peptides

Safety notes

TB-500 is not approved by the TGA for human use in Australia, and controlled human safety data is lacking. Because product purity on the grey market cannot be verified and long-term effects are unknown, caution is warranted. Anyone with an injury or health concern should consult a qualified healthcare professional.

References

  1. PubMed, Thymosin Beta-4 research literature
  2. PubMed, TB-500 / Thymosin Beta 4 tissue repair
  3. TGA, Therapeutic Goods Administration